T-cell-mediated immune responses against different cancer types are restored by immune checkpoint inhibitors (ICIs), such as monoclonal antibodies that block cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death 1 (PD-1), or its ligand (PD-L1) [3]. Here, CTLA4 is linked to cancer.